Jing Xi, MD, MPH

Clifton, K., Thomas, SN., Luo J., Xi, J., Bagegni, NA., Ademuyiwa, FO., Suresh, R., Frith, A., Davis, AA., Bose, R., Weilbaecher, K., Hensing WL., Pluard T., Cristofanilli M., Han HS., Brufsky AM., Kalinsky K., Goel S., Wander SA., Peterson LL., Ma, CX. Clinical outcomes of patients with HR+ HER2- advanced breast cancer with early progression on CDK4/6 inhibitors. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX. Dec 6-10, 2022 [spotlight poster]

Xi, J., Luo, J., O’Sullivan, C., Chen, N., Stringer-Reasor, E., Ma, C., Campian, J. Phase II Study of the Combination of Liposomal Irinotecan and Pembrolizumab for Triple-Negative Breast Cancer with Brain Metastases. 2022 Annual Conference on CNS Clinical Trials and Brain Metastases. Toronto, Canada. Aug 12-13, 2022

Xi, J., Harnden, K., Call, G., Mauer, E., Ronski, K., Luo, J., Ma, C*, and Vasan, N. Genomic landscape of HER2-negative advanced or metastatic breast cancer with PIK3CA gain-of-function mutations. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX. Dec 7-10, 2021

Brett, J., Dubash, T., Niemierko, A., Mariotti, V., Kim, L., Xi, J., Pandey, A., Dunne, S., Nasrazadani, A., Lloyd, MR., Spring, LM., Micalizzi, D., Onozato, M., Che, D., Brufsky, A., Kalinsky, K., Ma, CX., O’Shaughnessy, J., Han, HS., Iafrate, J., Maheswaran, S., Haber, DA., Bardia, A., Wander, SA. Association between co-existing genomic alterations and abemaciclib benefit in patients with metastatic hormone receptor-positive breast cancer with ESR1 mutations following disease progression on prior endocrine therapy plus palbociclib or ribociclib. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX. Dec 7-10, 2021 [spotlight poster]

Xi, J., Bagegni, N., Ademuyiwa, F., Frith, A., Suresh, R., Roshal, A., Rigden, C., Hernandez-Aya, L., Peterson, L., Opyrchal, M., Clifton, K., Weilbaecher, K., Bose, R., Ma CX. Circulating tumor DNA mutation profile in relation to palbociclib efficacy in hormone receptor positive and HER2 negative metastatic breast cancer. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX. Dec 8-12, 2020

Wander, S., Han, H., Johnson, G., Lloyd, M., Mao, P., Nayar, U., Kowalski, K., Stein, C., Mariotti, Kim, L., Xi, J., Pandey, A., Dunne, S., Nasrazadani, A., Brufsky, A., Kalinsky, K., Ma, C., O’Shaughnessy, J., Wagle, N., Bardia, A. ESR1 mutation as a potential predictor of abemaciclib benefit following prior CDK4/6 inhibitor (CDK4/6i) progression in hormone receptor-positive (HR+) metastatic breast cancer (MBC): a translational investigation. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX. Dec 8-12, 2020

Wander, S., Zangardi, M., Niemierko, A., Kambadakone, A., Kim L., Xi, J., Pandey, A., Spring, L., Stein, C., Juric D., Kuter, I., Moy, B., Mulvey, T., Vidula, N., Isakoff, S., Yuen, M., Brufsky, A., Ma, C., O’Shuanghnessy, J., Bardia, A. A Multi-center Analysis of Abemaciclib after Progression on Palbociclib in Patients with Hormone Receptor-positive/HER2- Metastatic Breast Cancer. American Society of Clinical Oncology (ASCO) Meeting, Chicago, IL. May 31 – June 4, 2019. Same abstract published in JCO 2019; 37 (15_Suppl)

Xi, J.*, Oza, A.*, Thomas, S., Naughton, M., Ademuyiwa, F., Weilbaecher, K., Suresh, R., Bose, R., Cherian, M., Hernandez-Aya, L., Frith, A., Peterson, L., Luo, J., Krishnamurthy, J., Ma, C. Retrospective Review of Palbociclib Efficacy and Benefit from Subsequent Treatments Following Palbociclib Progression in Patients with Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX. Dec 5-9, 2017. Same abstract published
in AACR 2018; 78(4_Suppl)

Tavris, D., Wang, C., Chu H., Xi J., Nie L., Jacobs S., Duggirala H., Pinnow E. Assessing Publication Bias from Clinical Studies of Coronary Artery Stents. International Society for Pharmacoepidemiology (ISPE) Annual Conference, Chicago, IL. Aug 14-17, 2011

Xi, J. An Overlooked Sexual Orientation Health Disparities in Female Breast Cancer Screening. The Michigan Meeting 2010: The Economy and Cancer Health Disparities, Ann Arbor, MI. May 20-22, 2010

Peer-Reviewed Journal Articles

Brett, J., Dubash, T., Johnson, G., Niemierko, A., Mariotti, V., Kim, L., Xi, J., Pandey, A., Dunne, S., Nasrazadani, A., Lloyd, M., Kambadadone, A., Spring, L., Micalizzi, D., Onozato, M., Che, D., Nayar, U., Brufksy, A., Kalinsky, K., Ma, C., O'Shaughnessy, J., Han, H., Iafrate, A., Ryan, L., Juric, D., Moy, B., Ellisen, L., Maheswaran, S., Wagle, N., Haber, D., Bardia, A., and Wander S. A gene panel associated with abemaciclib utility in ESR1-mutated breast cancer after prior CDK4/6-inhibitor progression. Journal of Clinical Oncology (JCO) Precision Oncology. 2023 [Accepted]

Wander, S., Zangardi, M., Niemierko, A., Kambadakone, A., Kim L., Xi, J., Pandey, A., Spring, L., Stein, C., Juric D., Kuter, I., Moy, B., Mulvey, T., Vidula, N., Isakoff, S., Yuen, M., Brufsky, A., Ma, C., O’Shuanghnessy, J., Bardia, A. A Multi-center Analysis of Abemaciclib after Progression on Palbociclib in Patients with Hormone Receptor-positive/HER2- Metastatic Breast Cancer. Journal of the National Comprehensive Cancer Network (JNCCN) 2021 Mar 24:1-8: [Epub ahead of print]

Xi, J.*, Hassan, B.*, Katumba, R., Khaddour, K., Govindan, A., Luo, J., Huang, J., Campian, JL. The Predictive Value of Absolute Lymphocyte Counts on Tumor Progression and Pseudoprogression in Patients with Glioblastoma. BMC Cancer 2021 Mar 16:21(1): 285

Xi, J., Cynthia X. Ma. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor? Current Oncology Reports 2020; 22 (6): 57.

Xi, J.*, Oza, A.*, Thomas, S., Ademuyiwa, F., Weilbaecher, K., Suresh, R., Bose, R., Cherian, M., Hernandez-Aya, L., Frith, A., Peterson, L., Luo, J., Krishnamurthy, J., Ma, C. Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer. Journal of the National Comprehensive Cancer Network (JNCCN) 2019; 17(2): 141-147.

Patel, D.*, Xi, J.*, Luo, J., Ma, C., Campian, J. Neutrophil to Lymphocyte Ratio as a Predictor of Survival in Patients with Triple-Negative Breast Cancer. Breast Cancer Research and Treatment 2019; 174(2): 443-452.

Yang, C.*, Xi, J.*, Sheikh, S., Hakim, A., Nadella, S., Dhital, S., MD; Meier, M., Nnanna, O., Meyers, D. A Scoring System for Prediction and Risk Stratification of CO2 Narcosis Among Hospitalized Patients. Emergency Medicine 2018; 8(2):368.

Book Chapters

Xi, J., Ma, C., Clifton, K. Chapter 13. Breast Cancer. The Washington Manual of Oncology. 4th edition. 2021

Committee on Review of California Institute for Regenerative Medicine (CIRM) (Group Author). The California Institute for Regenerative Medicine: Science, Governance, and the Pursuit of Cures. 2012. Washington, DC: The National Academies Press.

Committee on Advancing Pain Research, Care, and Education (Group Author). Relieving Pain in America – A Blueprint for Transforming Prevention, Treatment, and Research. 2011. Washington, DC: The National Academies Press.